ALK and neuroblastoma: In a recent study, Infarinato and colleagues have shown that PF06463922, a highly potent ALK inhibitor for wild-type ALK and various ALK mutants, exhibits superior antitumor activity in neuroblastoma xenografts harboring the ALK F1174L mutation (Infarinato et al., 2016), providing a rationale for assessing the efficacy of newer generation ALK inhibitors in clinical trials for treating patients with ALK-mutated neuroblastoma.